2009 – Ongoing: A Study of SCH 900518 in Previously Untreated Subjects with Genotype 1 Chronic Hepatitis C. P05104-NEXT 1. Sponsor: Schering Plough Research Institute. Sub-Investigator.
2008 – 2010: A Phase 3, Safety and Efficacy Study of Beceprevir in Previously Untreated subjects with Chronic Hepatitis C Genotype 1. P05216-SPRINT 2. Sponsor: Schering Plough Research Institute. Sub-Investigator.
2008 – 2010: A Phase 3, Safety and Efficacy Study of Beceprevir in Subjects with Chronic Hepatitis C Genotype 1 Who Failed prior Treatment with Peg interferon/Ribavirin.. P05101-RESPOND 2. Sponsor: Schering Plough Research Institute. Sub-Investigator.
2008 – 2008: A multi-center, investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis. Protocol 2007021. Sponsor: Procter & Gamble Company. Sub-Investigator.
2007 – 2008: Protocol Title: A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects with Chronic Hepatitis C Protocol No.: P03523. Sponsor: Schering Plough Research Institute. Sub-Investigator.
2007 – Ongoing: Randomized, Observational Study of Entecavir to assess Long-term Outcomes Associated with Nucleoside/Nucleotide Monotherapy for Patients with
Chronic HVB Infection: Protocol No.: The REALM Study AI463080. Sub-Investigator
2004 – 2007 Comparison of PEG-IntronÒ 1.5 mcg/kg/wk Plus REBETOLÒ vs PEG-IntronÒ 1 mcg/kg/wk Plus REBETOLÒ vs PEGASYSâ 180 mcg/wk Plus COPEGUSä in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1, Protocol No.: P03471. Sponsor: Schering Plough Research Institute. Sub-Investigator.
1. Doherty TA, DuFrayne FJ, McCarthy MD, Duckworth KS. Heart Transplantations A Case Report. Temple MD, Vol. 1, No. 2. Spring, 1986
2. DuFrayne FJ, Aronchick CA, Draganescu J, Wright SH, Lipshutz WH. Patients with Metastatic Pelvic Malignancy are Predisposed to Chronic Intestinal Obstruction. Gastroenterology, Vol. 94, A109. 1988
3. DuFrayne FJ, Sample M, Katzka DA, Lichtenstein GR, Ouyang A. Prevalence and Reversibility of Major Esophageal Motor Abnormalities in Patients with Gastroesophageal Reflux Disease. American Journal of Gastroenterology, Vol. 86, #9, p 1297. Sept. 1991
4. Ouyang A, Stecker M, DuFrayne FJ. Electrical Evoked Responses to Rectal Distention - An Objective Measurement Of The Sensory Pathway From The Gut. American Motility Society Biennial Symposium,
5. Shields D, DuFrayne FJ, Aronchick CA, Lipshutz WH, Wright SH. Balloon Dilatation and Biliary Prosthesis in Treatment of Post Sphincterotomy Stenosis. American Journal of Gastroenterology, 89:9, Page 1665 Sept 1994
6. Aronchick CA, Lipshutz WH, Wright SH, DuFrayne FJ. Bicap Cautery Converts Barrett’s Epithelium to Squamous Mucosa. American Journal of Gastroenterology September 1995, 90:9, p1554. Presented at the Annual Society Meeting of American College of Gastroenterology, New York, NY, October 1995
7. A New Patient Friendly Colonic Purgative, Controlled Trial vs. Colyte® and Fleets Phoso®Soda (FP). Aronchick CA, Lipshutz WH, Wright SH, DuFrayne FJ. Pennsylvania Hospital., Philadelphia, Pa.AJG. Vol. 93, No. 9, 1998.
8. Aronchick CA, Lipshutz WH, Wright SH, DuFrayne FJ. Pennsylvania Hospital Phila. Pa. A Novel Tableted Purgative for Colonoscopic Preparation: Efficacy and Safety Comparisons with Colyte (R) and Fleets (R)Phospho(R)Soda. American Society of Gastroenterology, published in Gastro End. Sept. 2000:52:3, pp. 346-352.
9. SA Gregory, FJ DuFrayne, et al. Pennsylvania Hospital, Philadelphia, Pa. Use of Non-Positive Ventilation (BiPAP) during PEG Placement in Patients with ALS and FVC<50%. Presented at the 53rd Annual Meeting of the American College of Neurology May, 2001.
Postoperative Gastrointestinal Dysfunction. Chapter 67, Goldman DR, Brown FH, Guarnieri DM (ed). Perioperative Medicine, McGraw-Hill, Inc.